Table 1.
Clinical and pathological characteristics of the ALOX15high and ALOX15low ER+ groups in our cohort.
| Variables | ALOX15high | ALOX15low | p |
|---|---|---|---|
| Number of patients | 70 (47.0%) | 79 (53.0%) | |
| Age at diagnosis (years) | 55.28 ± 10.82 | 55.33 ± 10.72 | 0.964 |
| HER2 status | 0.989 | ||
| Positive | 15 (21.4%) | 17 (21.5%) | |
| Negative | 55 (78.6%) | 62 (78.5%) | |
| T stage | 0.013 | ||
| I | 38 (54.3%) | 58 (73.4%) | |
| II | 28 (40.0%) | 21 (26.6%) | |
| III | 4 (5.7%) | 0 (0.0%) | |
| N stage | 0.219 | ||
| N0 | 42 (60.0%) | 55 (69.6%) | |
| N1–N3 | 28 (40.0%) | 24 (30.4%) | |
| Stage | 0.060 | ||
| I | 28 (40.0%) | 47 (59.5%) | |
| II | 29 (41.4%) | 22 (27.8%) | |
| III | 13 (18.6%) | 10 (12.7%) | |
| Ki-67 | 0.20 | 0.19 | 0.653 |
| Histological grade* | 0.382 | ||
| G1 | 3 (4.8%) | 4 (5.8%) | |
| G2 | 52 (82.5%) | 61 (88.4%) | |
| G3 | 8 (12.7%) | 4 (5.8%) | |
| Vascular invasion* | 0.043 | ||
| Yes | 23 (36.5%) | 15 (20.8%) | |
| No | 40 (63.5%) | 57 (79.2%) |
* Some patients were not evaluated.
The bold values mean that they are less than 0.05.